Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 55 clinical trials
A Youth-Brief Tobacco Intervention (Y-BTI) for High School Youth (Y-BTI)

evaluate a universal group-based Youth Brief Tobacco Intervention (Y-BTI) plus mobile phone automated text messaging (ATM) for 9th grade students. This study will use a sequential, multi-method

tobacco smoke
motivational interviewing
Accepts healthy volunteers
  • 0 views
  • 16 Jun, 2022
  • 1 location
A Study of Reduced-dose Radiation in People With Metastatic Tumors With a Genetic Change

This study will test whether reduced-dose radiotherapy is an effective treatment for metastatic tumors with an ATM mutation. The researchers want to find the lowest dose of radiation that would

  • 0 views
  • 01 Oct, 2021
  • 7 locations
Study of Olaparib in Metastatic Renal Cell Carcinoma Patients With DNA Repair Gene Mutations (ORCHID)

Single arm, single site, open-label Phase II study of the effects of oral olaparib in participants with metastatic renal cell carcinoma that harbor an inactivating mutation in BAP-1, ATM

cytokines
rad51c
CHEK2
BRCA2
hysterectomy
  • 21 views
  • 09 Feb, 2022
  • 1 location
Trial of XRD-0394 a Kinase Inhibitor in Combination With Palliative Radiotherapy in Advanced Cancer Patients

XRD-0394 is a novel, potent, oral, small molecule dual inhibitor of ataxia telangiectasia mutated kinase (ATM) and deoxyribonucleic acid (DNA)-dependent protein kinase (DNA-PK) that has

cancer
  • 2 views
  • 07 Oct, 2021
  • 2 locations
Olaparib In Metastatic Breast Cancer

This research study is for patients with metastatic breast cancer. Metastatic means that the cancer has spread beyond the breast. In addition, through genetic testing of the blood or tumor, an altered gene has been found that suggests the tumor may not be able to repair its genetic material (DNA) …

bisphosphonates
denosumab
doxorubicin
immunological adjuvant
BRCA2
  • 220 views
  • 12 Jul, 2022
  • 18 locations
Chk2 Inhibitor for Recurrent EpitheliAl periToneal fallopIan or oVarian cancEr (CREATIVE Phase IA Trial)

that is a checkpoint kinase binding specifically to CHK2, rather than CHK1, and it inhibits the DDR system by inhibiting the ATM-CHK2 pathway, which is activated in response to DSBs. When a high-grade

  • 2 views
  • 29 Jan, 2021
  • 1 location
Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy

Hyperbaric oxygen therapy (HBOT) utilizes 100% oxygen delivery at a pressure greater than 1 atm for the treatment of various emergent medical conditions including carbon monoxide poisoning. The

  • 0 views
  • 25 Mar, 2022
  • 1 location
Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

This phase II trial studies how well olaparib works in treating patients with biliary tract cancer that has spread to other places in the body (metastatic) and with aberrant DNA repair gene mutations. Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell …

platelet count
follicle stimulating hormone
absolute neutrophil count
palb2
oophorectomy
  • 0 views
  • 29 May, 2022
  • 5 locations
Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

This phase II trial studies how well docetaxel with carboplatin followed by rucaparib camsylate works in treating patients with metastatic castration resistant prostate cancer (spread outside of prostate and resistant to testosterone suppression) with homologous recombination DNA repair deficiency. Chemotherapy drugs, such as docetaxel and carboplatin, work to stop the …

gonadotropin
lhrh analogue
bone scan
androgen
adenocarcinoma of prostate
  • 28 views
  • 30 Jun, 2022
  • 1 location
A Study of APG-115 in Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors

Part 1 is the dose escalation of APG-115 in combination with label dose of pembrolizumab. Part 2 is phase II design of APG-115 at recommended phase 2 dose (RP2D) in combination with pembrolizumab.

alopecia
carcinoma
programmed cell death protein 1
growth factor
measurable disease
  • 34 views
  • 27 Jul, 2022
  • 19 locations